Cannabis Stock to IPO on NASDAQ in Less Than Two Weeks

Yesterday, Zynerba Pharmaceuticals announced the terms of its upcoming initial public offering (IPO). The Pennsylvania-based company plans to raise $42 million by offering 3 million shares in the $13-$15 range. At the midpoint of the proposed range, it would have a fully diluted market value of $128 million. Shares are expected to commence trading during the week of August 3, 2015, on the NASDAQ under the symbol ZYNE.

Investors and financial institutions have been patiently waiting for a new cannabis-related company to commence trading on a national exchange. GW Pharmaceuticals (GWPH) and INSYS Therapeutics, Inc. (INSY) are two NASDAQ traded biotech companies that are focused on developing treatments derived from cannabis.  During the last two years, GWPH and INSY are up 1163% and 614% respectively and they are currently trading at very rich valuations.

Developing treatments for five debilitating diseases

Zynerba Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The company is developing two therapeutic candidates. These are:

• THC Pro-Drug Patch – ZYN001: ZYN001 is a pro-drug of THC that enables transdermal delivery via a patch. Zynerba is studying ZYN001 in patients with fibromyalgia and peripheral neuropathic pain. Zynerba expects to initiate ZYN001 Phase 1 clinical studies in the second quarter of 2016.
• CBD Gel – ZYN002: ZYN002 is the first and only synthetic CBD formulated as a patient-protected permeation-enhanced gel for transdermal delivery. Zynerba is studying ZYN002 in patients with refractory epilepsy, Fragile X syndrome and osteoarthritis. Zynerba expects to initiate ZYN002 Phase 1 clinical studies in the third quarter of 2015.

Outlook

We expect Zynerba’s IPO to be a profitable investment due to the strong demand for cannabis related investments from investors and financial institutions who want to invest in company that trades on a national stock exchange (not the OTC).

Zynerba will fill this need for many investors and we will keep you updated on developments related to its IPO.

To learn how to capitalize on this investment, click here!  

Share

Tags

Michael Berger is Managing Partner of StoneBridge Partners, LLC and Founder of Technical420.com. Prior to entering the cannabis industry, Michael was an Equity Research Analyst at Raymond James Financial covering the Energy Sector. Michael has been featured in publications such as The Street, Bloomberg, US Money News, and hosts various cannabis events across North America.

Top Stories